Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $39.3300 (-1.16%) ($39.3300 - $39.3300) on Mon. Jun. 28, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.93% (three month average) | RSI | 63 | Latest Price | $39.3300(-1.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.8% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.4% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) IWO(59%) ARKK(58%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.465% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.465% (StdDev 2.93%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $38.63(1.81%) | 10 Day Moving Average | $38.08(3.28%) | 20 Day Moving Average | $37.29(5.47%) | To recent high | -19.3% | To recent low | 21.3% | Market Cap | $4.981b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |